Search Results - "Manro, Jason R"

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy by Schaer, David A, Geeganage, Sandaruwan, Amaladas, Nelusha, Lu, Zhao Hai, Rasmussen, Erik R, Sonyi, Andreas, Chin, Darin, Capen, Andrew, Li, Yanxia, Meyer, Catalina M, Jones, Bonita D, Huang, Xiaodong, Luo, Shuang, Carpenito, Carmine, Roth, Kenneth D, Nikolayev, Alexander, Tan, Bo, Brahmachary, Manisha, Chodavarapu, Krishna, Dorsey, Frank C, Manro, Jason R, Doman, Thompson N, Donoho, Gregory P, Surguladze, David, Hall, Gerald E, Kalos, Michael, Novosiadly, Ruslan D

“…Combination strategies leveraging chemotherapeutic agents and immunotherapy have held the promise as a method to improve benefit for patients with cancer…”
Get full text

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade by Holmgaard, Rikke B, Schaer, David A, Li, Yanxia, Castaneda, Stephen P, Murphy, Mary Y, Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R, Iversen, Philip W, Surguladze, David, Hall, Gerald E, Novosiadly, Ruslan D, Benhadji, Karim A, Plowman, Gregory D, Kalos, Michael, Driscoll, Kyla E

“…TGFβ signaling plays a pleotropic role in tumor biology, promoting tumor proliferation, invasion and metastasis, and escape from immune surveillance…”
Get full text

Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3 by Atkinson, Jennifer M, Rank, Kenneth B, Zeng, Yi, Capen, Andrew, Yadav, Vipin, Manro, Jason R, Engler, Thomas A, Chedid, Marcio

“…It has previously been observed that a loss of β-catenin expression occurs with melanoma progression and that nuclear β-catenin levels are inversely…”
Get full text

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models by Li, Yanxia, Amaladas, Nelusha, O'Mahony, Marguerita, Manro, Jason R, Inigo, Ivan, Li, Qi, Rasmussen, Erik R, Brahmachary, Manisha, Doman, Thompson N, Hall, Gerald, Kalos, Michael, Novosiadly, Ruslan, Puig, Oscar, Pytowski, Bronislaw, Schaer, David A

“…Prolonged activation of vascular endothelial growth factor receptor-2 (VEGFR-2) due to mis-regulation of the VEGF pathway induces aberrant blood vessel…”
Get full text

Developmental expression of the major human hepatic CYP3A enzymes by Stevens, Jeffrey C, Hines, Ronald N, Gu, Chungang, Koukouritaki, Sevasti B, Manro, Jason R, Tandler, Peter J, Zaya, Matthew J

“…The human cytochrome P4503A forms show expression patterns subject to developmental influence. CYP3A7 and CYP3A4 are generally classified as the major fetal…”
Get more information

Developmental expression of human hepatic CYP2C9 and CYP2C19 by Koukouritaki, Sevasti B, Manro, Jason R, Marsh, Sandra A, Stevens, Jeffrey C, Rettie, Allan E, McCarver, D Gail, Hines, Ronald N

“…The CYP2C subfamily is responsible for metabolizing many important drugs and accounts for about 20% of the cytochrome p450 in adult liver. To determine…”
Get more information

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor by Yingling, Jonathan M, McMillen, William T, Yan, Lei, Huang, Huocong, Sawyer, J Scott, Graff, Jeremy, Clawson, David K, Britt, Karen S, Anderson, Bryan D, Beight, Douglas W, Desaiah, Durisala, Lahn, Michael M, Benhadji, Karim A, Lallena, Maria J, Holmgaard, Rikke B, Xu, Xiaohong, Zhang, Faming, Manro, Jason R, Iversen, Philip W, Iyer, Chandrasekar V, Brekken, Rolf A, Kalos, Michael D, Driscoll, Kyla E

“…Transforming growth factor-β (TGFβ) is an important driver of tumor growth via intrinsic and extrinsic mechanisms, and is therefore an attractive target for…”
Get full text

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth by Liu, Ling, Zeng, Wei, Wortinger, Mark A, Yan, S Betty, Cornwell, Paul, Peek, Victoria L, Stephens, Jennifer R, Tetreault, Jonathan W, Xia, Jinqi, Manro, Jason R, Credille, Kelly M, Ballard, Darryl W, Brown-Augsburger, Patricia, Wacheck, Volker, Chow, Chi-Kin, Huang, Lihua, Wang, Yong, Denning, Irene, Davies, Julian, Tang, Ying, Vaillancourt, Peter, Lu, Jirong

“…MET, the receptor for hepatocyte growth factor (HGF), has been implicated in driving tumor proliferation and metastasis. High MET expression is correlated with…”
Get full text

Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein by Higgins, J William, Bao, Jing Q, Ke, Alice B, Manro, Jason R, Fallon, John K, Smith, Philip C, Zamek-Gliszczynski, Maciej J

“…Although organic anion transporting polypeptide (OATP)-mediated hepatic uptake is generally conserved between rodents and humans at a gross pharmacokinetic…”
Get full text

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer by Köhler, Jens, Zhao, Yutong, Li, Jiaqi, Gokhale, Prafulla C, Tiv, Hong L, Knott, Aine R, Wilkens, Margaret K, Soroko, Kara M, Lin, Mika, Ambrogio, Chiara, Musteanu, Monica, Ogino, Atsuko, Choi, Jihyun, Bahcall, Magda, Bertram, Arrien A, Chambers, Emily S, Paweletz, Cloud P, Bhagwat, Shripad V, Manro, Jason R, Tiu, Ramon V, Jänne, Pasi A

“…gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB…”
Get full text

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy by Du, Jian, Yan, Lei, Torres, Raquel, Gong, Xueqian, Bian, Huimin, Marugán, Carlos, Boehnke, Karsten, Baquero, Carmen, Hui, Yu-Hua, Chapman, Sonya C, Yang, Yanzhu, Zeng, Yi, Bogner, Sarah M, Foreman, Robert T, Capen, Andrew, Donoho, Gregory P, Van Horn, Robert D, Barnard, Darlene S, Dempsey, Jack A, Beckmann, Richard P, Marshall, Mark S, Chio, Li-Chun, Qian, Yuewei, Webster, Yue W, Aggarwal, Amit, Chu, Shaoyou, Bhattachar, Shobha, Stancato, Louis F, Dowless, Michele S, Iversen, Phillip W, Manro, Jason R, Walgren, Jennie L, Halstead, Bartley W, Dieter, Matthew Z, Martinez, Ricardo, Bhagwat, Shripad V, Kreklau, Emiko L, Lallena, Maria Jose, Ye, Xiang S, Patel, Bharvin K R, Reinhard, Christoph, Plowman, Gregory D, Barda, David A, Henry, James R, Buchanan, Sean G, Campbell, Robert M

“…Although Aurora A, B, and C kinases share high sequence similarity, especially within the kinase domain, they function distinctly in cell-cycle progression…”
Get full text

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping by Yan, S. Betty, Um, Suzane L., Peek, Victoria L., Stephens, Jennifer R., Zeng, Wei, Konicek, Bruce W., Liu, Ling, Manro, Jason R., Wacheck, Volker, Walgren, Richard A.

“…Summary Purpose Approximately 3% of lung cancer bears mutations leading to MET exon 14 skipping, an oncogenic driver which is further evidenced by case reports…”
Get full text

Inhibition of Tumor Growth and Metastasis in Non―Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET by WENJUAN WU, CHEN BI, CREDILLE, Kelly M, MANRO, Jason R, PEEK, Victoria L, DONOHO, Gregory P, LEI YAN, WIJSMAN, John A, YAN, S. Betty, WALGREN, Richard A

“…Lung cancer is the leading cause of cancer-related death worldwide. Sustained activation, overexpression, or mutation of the MET pathway is associated with a…”
Get full text

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models by Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.

“…Summary The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell…”
Get full text

Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles by Wickremsinhe, Enaksha R, Huang, Naijia H, Abdul, Basira G, Knotts, Kirk, Ruterbories, Kenneth J, Manro, Jason R

“…Understanding the distribution of the analyte between the cellular and noncellular (plasma) components of the blood is important, especially in situations…”
Get full text

How well do lipophilicity parameters, MEEKC microemulsion capacity factor, and plasma protein binding predict CNS tissue binding? by Zamek-Gliszczynski, Maciej J, Sprague, Karen E, Espada, Alfonso, Raub, Thomas J, Morton, Stuart M, Manro, Jason R, Molina-Martin, Manuel

“…Brain fraction unbound (Fu) is critical to understanding the pharmacokinetics/dynamics of central nervous system (CNS) drugs, thus several surrogate predictors…”
Get more information

Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors by Ryder, John W, Falcone, Julie F, Manro, Jason R, Svensson, Kjell A, Merchant, Kalpana M

“…The biarylpropylsulfonamide class of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) potentiators represented by…”
Get more information

Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD) by Bhagwat, Shripad V., Zhao, Baohui, Shen, Weihua, Mur, Cecilia, Barr, Robert, Kindler, Lisa J., Rubio, Almudena, Bastian, Jolie A., Cohen, Jeffrey D., Mattioni, Brian E., Yuen, Eunice, Baker, Thomas K., Castanares, Mark A., Fei, Dongling, Manro, Jason R., Lallena, Maria Jose, Peng, Sheng-Bin, de Dios, Alfonso

“…Abstract Nearly 70% of newly diagnosed breast cancers are estrogen receptor alpha (ERα) positive, for which endocrine therapy is a primary treatment. However,…”
Get full text

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations by Forest, Amelie, Rasmussen, Erik R., Doman, Thompson N., Amatulli, Michael, Bassi, Rajiv, Hall, Gerald E., Manro, Jason R., Brahmachary, Manisha, Surguladze, David, Yao, Yung-mae M., Kalos, Michael D., Novosiadly, Ruslan D.

“…Abstract First- , second- , and third-generation EGFR tyrosine kinase inhibitors (TKIs) demonstrate profound tumor responses in EGFR mutation-positive NSCLC…”
Get full text

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models by Melchior, Maxine A., Guo, Xuemei, Donoho, Gregory P., Iversen, Philip W., Doman, Thompson N., Brahmachary, Manisha, Gong, Xueqian, Hall, Gerald E., Manro, Jason R., Yao, Yung-mae M., Buchanan, Sean, Smeal, Tod, Kalos, Michael D., Novosiadly, Ruslan D.

“…Abstract Necitumumab (Nmab) in combination with chemotherapy has demonstrated overall survival benefit in patients with advanced or metastatic squamous…”
Get full text